Drug development is at risk from proposed takeover of AstraZeneca

16-05-2014 BMJ NewsComments (0)


Development of important and potentially lifesaving drugs could be disrupted and delayed if a proposed takeover of AstraZeneca by the giant US drug company Pfizer goes ahead, MPs have been told. The impact of such a takeover was discussed at an evidence session on 13 May of the House of Commons Business, Innovation and Skills Committee as part of its inquiry into the future of the UK drug company AstraZeneca


Read more on BMJ News

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top